Clinical efficacy of ABO-incompatible living donor liver transplantation: a Meta analysis
10.3969/j.issn.1674-7445.2018.04.004
- VernacularTitle:ABO血型不合活体肝移植术后疗效的Meta分析
- Author:
Qiang LIU
1
;
Fangbiao LUO
;
Xiong YAN
;
Shiqiao LUO
;
Chengyou DU
Author Information
1. 400016,重庆医科大学附属第一医院肝胆外科
- Keywords:
Liver transplantation;
Living donor;
Blood incompatibility;
ABO blood group system;
Meta-analysis;
Rejection response;
Biliary complication;
Hepatic artery embolization
- From:
Organ Transplantation
2018;9(4):261-267
- CountryChina
- Language:Chinese
-
Abstract:
Objective To systematically evaluate the clinical efficacy of ABO-incompatible living donor liver transplantation (ABO-I LDLT) and compare with ABO-compatible LDLT (ABO-C LDLT). Methods A systematic search of multiple databases at home and abroad was conducted to retrieve the literatures related to the statistical comparison of clinical efficacy between ABO-I LDLT and ABO-C LDLT. The literature screening was conducted, the quality of literatures was evaluated and data extraction was performed. Using Rev Man 5.3 software, a Meta-analysis was performed by random effect model or fixed effect model. Results A total of 432 articles were searched, and 6 articles published in English were eventually included according to the inclusion criteria. The Meta-analysis demonstrated that there was no significant difference in the postoperative 1-, 3- and 5-year survival rate of the recipients and grafts and the incidence of rejection responses between the ABO-I LDLT and ABO-C LDLT groups (all P≥0.05). The incidence of postoperative biliary complications and hepatic artery embolization in the ABO-I LDLT group was significantly higher than that in the ABO-C LDLT group [odds ratio (OR)=2.08, 95% confidence interval (CI) 1.25-3.45, P=0.005; OR=2.24, 95%CI 1.03-4.89, P=0.04]. Conclusions Compared with the ABO-C LDLT, ABO-I LDLT yields lower clinical efficacy, whereas it is still an effective method for the treatment of end-stage liver disease.
